

Levamisole / Oxfendazole Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 1.2
 30.09.2023
 10808164-00003
 Date of first issue: 05.07.2022

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Levamisole / Oxfendazole Formulation

Manufacturer or supplier's details

Company : MSD

Address : Rua Coronel Bento Soares, 530

Cruzeiro - Sao Paulo - Brazil CEP 12730-340

Telephone : 908-740-4000

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification in accordance with ABNT NBR 14725 Standard

Acute toxicity (Oral) : Category 5

Reproductive toxicity : Category 1B

Short-term (acute) aquatic

hazard

Category 1

Long-term (chronic) aquatic

hazard

: Category 2

GHS label elements in accordance with ABNT NBR 14725 Standard

Hazard pictograms :





Signal Word : Danger

Hazard Statements : H303 May be harmful if swallowed.

H360FD May damage fertility. May damage the unborn child.

H400 Very toxic to aquatic life.

H411 Toxic to aquatic life with long lasting effects.

Precautionary Statements : Prevention:

P201 Obtain special instructions before use.



Levamisole / Oxfendazole Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 1.2
 30.09.2023
 10808164-00003
 Date of first issue: 05.07.2022

P273 Avoid release to the environment.

P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection.

Response:

P312 Call a POISON CENTER/ doctor if you feel unwell.

P391 Collect spillage.

Storage:

P405 Store locked up.

Other hazards which do not result in classification

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Classification	Concentration (% w/w)
Levamisole hydrochloride	16595-80-5	Acute toxicity (Oral), Category 3 Reproductive toxicity, Category 2 Specific target organ toxicity - repeated exposure (Oral) (Blood, Testis), Category 2 Short-term (acute) aquatic hazard, Category 3 Long-term (chronic) aquatic hazard, Category 3	>= 5 -< 10
oxfendazole	53716-50-0	Reproductive toxicity, Category 1B Specific target organ toxicity - repeated exposure (Liver, Tes- tis), Category 2 Short-term (acute) aquatic hazard, Category 1 Long-term (chronic) aquatic hazard, Category 1 Category 1	>= 2,5 -< 5
Polyethylene glycol stearate	9004-99-3		>= 1 -< 5
Citric acid	77-92-9	Eye irritation, Category 2A Specific target organ toxicity - single expo- sure, Category 3	>= 1 -< 5



Levamisole / Oxfendazole Formulation

Version **Revision Date:** SDS Number: Date of last issue: 04.04.2023 30.09.2023 10808164-00003 Date of first issue: 05.07.2022 1.2

SECTION 4. FIRST AID MEASURES

General advice In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse. Flush eyes with water as a precaution.

In case of eye contact

Get medical attention if irritation develops and persists.

If swallowed If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

Most important symptoms

and effects, both acute and

delayed

May be harmful if swallowed.

May damage fertility. May damage the unborn child.

Protection of first-aiders First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Treat symptomatically and supportively. Notes to physician

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire

fighting

Hazardous combustion prod: :

ucts

Carbon oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

Exposure to combustion products may be a hazard to health.

cumstances and the surrounding environment.

Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment:

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- : Use personal protective equipment.



Levamisole / Oxfendazole Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 1.2
 30.09.2023
 10808164-00003
 Date of first issue: 05.07.2022

tive equipment and emergency procedures

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions

Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g., by containment or

oil barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Soak up with inert absorbent material.

For large spills, provide diking or other appropriate

containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate

container.

Clean up remaining materials from spill with suitable

absorbent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

employed in the cleanup of releases. You will need to

determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe mist or vapors.

Do not swallow.

Avoid contact with eyes.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Keep container tightly closed.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working

place.

When using do not eat, drink or smoke.

Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

Conditions for safe storage : Keep in properly labeled containers.

Store locked up. Keep tightly closed.



Levamisole / Oxfendazole Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 1.2 30.09.2023 10808164-00003 Date of first issue: 05.07.2022

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

Explosives Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Levamisole hydrochloride	16595-80-5	TWA	20 μg/m3 (OEB 3)	Internal
	Further information: Skin			
		Wipe limit	200 μg/100 cm ²	Internal
oxfendazole	53716-50-0	TWA	40 μg/m3 (OEB 3)	Internal
		Wipe limit	400 μg/100 cm ²	Internal
Polyethylene glycol stearate	9004-99-3	TWA (Inhalable particulate matter)	10 mg/m³	ACGIH
		TWA (Respirable particulate matter)	3 mg/m³	ACGIH

Engineering measures: Use appropriate engineering controls and manufacturing

technologies to control airborne concentrations (e.g., drip-

less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of

the compound to uncontrolled areas (e.g., open-face

containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or

exposure assessment demonstrates exposures outside the

recommended guidelines, use respiratory protection.

Filter type Hand protection

Particulates type

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.



Levamisole / Oxfendazole Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 1.2 30.09.2023 10808164-00003 Date of first issue: 05.07.2022

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : Aqueous solution

Color : No data available

Odor : No data available

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

Autoignition temperature

: Not applicable

6/19

No data available



Levamisole / Oxfendazole Formulation

Version **Revision Date:** SDS Number: Date of last issue: 04.04.2023 30.09.2023 10808164-00003 Date of first issue: 05.07.2022 1.2

Decomposition temperature No data available

Viscosity

No data available Viscosity, kinematic

Explosive properties Not explosive

Oxidizing properties The substance or mixture is not classified as oxidizing.

Molecular weight No data available

Particle size Not applicable

SECTION 10. STABILITY AND REACTIVITY

Not classified as a reactivity hazard. Reactivity Stable under normal conditions. Chemical stability Can react with strong oxidizing agents.

Possibility of hazardous reac- :

tions

None known. Conditions to avoid Incompatible materials

Oxidizing agents Hazardous decomposition

products

No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of: Inhalation

Skin contact exposure

Ingestion Eye contact

Acute toxicity

May be harmful if swallowed.

Product:

Acute oral toxicity Acute toxicity estimate: 2.250 mg/kg

Method: Calculation method

Components:

Levamisole hydrochloride:

Acute oral toxicity LD50 (Rat): 180 mg/kg

LD50 (Mouse): 223 mg/kg

LD50 (Rabbit): 458 mg/kg

Remarks: No data available Acute inhalation toxicity

Acute dermal toxicity Remarks: No data available



Levamisole / Oxfendazole Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 1.2 30.09.2023 10808164-00003 Date of first issue: 05.07.2022

oxfendazole:

Acute oral toxicity : LD50 (Rat): > 6.000 mg/kg

LD50 (Dog): 1.600 mg/kg

LD50 (sheep): 250 mg/kg

Polyethylene glycol stearate:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

Citric acid:

Acute oral toxicity : LD50 (Mouse): 5.400 mg/kg

Acute dermal toxicity : LD50 (Rat): > 2.000 mg/kg

Method: OECD Test Guideline 402

Assessment: The substance or mixture has no acute dermal

toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:

Levamisole hydrochloride:

Remarks : No data available

oxfendazole:

Species : Rabbit

Result : No skin irritation

Polyethylene glycol stearate:

Species : Rabbit
Method : Draize Test
Result : No skin irritation

Citric acid:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Levamisole hydrochloride:

Remarks : No data available

oxfendazole:

Species : Rabbit



Levamisole / Oxfendazole Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 1.2
 30.09.2023
 10808164-00003
 Date of first issue: 05.07.2022

Result : No eye irritation

Polyethylene glycol stearate:

Species : Rabbit

Result : No eye irritation Method : Draize Test

Citric acid:

Species : Rabbit

Result : Irritation to eyes, reversing within 21 days

Method : OECD Test Guideline 405

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:

Levamisole hydrochloride:

Remarks : No data available

Polyethylene glycol stearate:

Test Type : Open epicutaneous test

Routes of exposure : Skin contact Species : Guinea pig Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:

Levamisole hydrochloride:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

oxfendazole:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow

cytogenetic test, chromosomal analysis)

Species: Mouse

Application Route: Oral

Result: positive



Levamisole / Oxfendazole Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 1.2
 30.09.2023
 10808164-00003
 Date of first issue: 05.07.2022

Polyethylene glycol stearate:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Citric acid:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: in vitro micronucleus test

Result: positive

Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow

cytogenetic test, chromosomal analysis)

Species: Rat

Application Route: Ingestion

Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Levamisole hydrochloride:

Species : Mouse Application Route : Oral Exposure time : 2 Years

NOAEL : 80 mg/kg body weight

Remarks : No significant adverse effects were reported

Species : Rat
Application Route : Oral
Exposure time : 2 Years

NOAEL : 40 mg/kg body weight

Remarks : No significant adverse effects were reported

oxfendazole:

Species : Rat
Application Route : Oral
Exposure time : 1 Years

Symptoms : No adverse effects.

Target Organs : Liver

Species : Rat
Application Route : Oral
Exposure time : 2 Years

Symptoms : No adverse effects.

Target Organs : Liver



Levamisole / Oxfendazole Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 1.2
 30.09.2023
 10808164-00003
 Date of first issue: 05.07.2022

Reproductive toxicity

May damage fertility. May damage the unborn child.

Components:

Levamisole hydrochloride:

Effects on fertility : Test Type: Three-generation reproduction toxicity study

Species: Rat

Application Route: Oral

Result: No significant adverse effects were reported

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Oral

Developmental Toxicity: NOAEL: 20 mg/kg body weight

Result: Fetotoxicity.

Test Type: Embryo-fetal development

Species: Rabbit Application Route: Oral

Developmental Toxicity: LOAEL: 40 mg/kg body weight

Result: Fetotoxicity.

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on development, based on

animal experiments.

oxfendazole:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat, male Application Route: Oral

Fertility: NOAEL: 17 mg/kg body weight

Target Organs: Testes Result: Effects on fertility.

Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Oral

Fertility: NOAEL: 0,9 mg/kg body weight

Target Organs: Liver

Result: No effects on fertility.

Test Type: Fertility Species: Mouse Application Route: Oral

Duration of Single Treatment: 1 Months Fertility: NOAEL: 750 mg/kg body weight

Target Organs: Testes Result: Effects on fertility.

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Oral

Developmental Toxicity: NOAEL: 10 mg/kg body weight

Result: positive, Fetal effects.



Levamisole / Oxfendazole Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 1.2 30.09.2023 10808164-00003 Date of first issue: 05.07.2022

Test Type: Embryo-fetal development

Species: Rat

Developmental Toxicity: NOAEL: 10 mg/kg body weight

Result: positive, Embryo-fetal toxicity.

Test Type: Embryo-fetal development

Species: Mouse

Application Route: Oral

Developmental Toxicity: NOAEL: 108 mg/kg body weight Result: positive, Embryo-fetal toxicity., Fetal abnormalities.

Test Type: Embryo-fetal development

Species: Rabbit Application Route: Oral

Developmental Toxicity: NOAEL: 0,625 mg/kg body weight

Reproductive toxicity - As-

sessment

Clear evidence of adverse effects on sexual function and fertility, based on animal experiments., Clear evidence of

adverse effects on development, based on animal

experiments.

Citric acid:

Effects on fetal development : Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

STOT-single exposure

Not classified based on available information.

Components:

Citric acid:

Assessment : May cause respiratory irritation.

STOT-repeated exposure

Not classified based on available information.

Components:

Levamisole hydrochloride:

Target Organs : Blood, Testis

Assessment : May cause damage to organs through prolonged or repeated

exposure.

: Oral

oxfendazole:

Routes of exposure

Target Organs : Liver, Testis

Assessment : May cause damage to organs through prolonged or repeated

exposure.



Levamisole / Oxfendazole Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 1.2 30.09.2023 10808164-00003 Date of first issue: 05.07.2022

Repeated dose toxicity

Components:

Levamisole hydrochloride:

Species : Rat
NOAEL : 2,5 mg/kg
Application Route : Oral
Exposure time : 18 Months
Target Organs : Testis

Species : Dog LOAEL : 20 mg/kg Application Route : Oral Exposure time : 18 Months Target Organs : Blood

Species : Dog LOAEL : 40 mg/kg Application Route : Oral Exposure time : 3 Months

oxfendazole:

Species : Rat

NOAEL : 11 mg/kg

Application Route : Oral

Exposure time : 2 Weeks

Target Organs : Blood, Liver, Testis

Species : Rat
NOAEL : 3,8 mg/kg
Application Route : Oral
Exposure time : 3 Months
Target Organs : Liver, Testis

Species : Mouse
NOAEL : 750 mg/kg
Application Route : Oral
Exposure time : 1 Months
Target Organs : Liver

Species : Mouse
NOAEL : 37,5 mg/kg
Application Route : Oral
Exposure time : 3 Months
Target Organs : Liver

Species : Dog
NOAEL : 6 mg/kg
Application Route : Oral
Exposure time : 1 Months

Remarks : No significant adverse effects were reported

Species : Dog NOAEL : 11 mg/kg



Levamisole / Oxfendazole Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 1.2
 30.09.2023
 10808164-00003
 Date of first issue: 05.07.2022

Application Route : Oral Exposure time : 2 Weeks

Target Organs : Lymph nodes, thymus gland

Species : Dog
NOAEL : 13,5 mg/kg
Application Route : Oral
Exposure time : 12 Months
Target Organs : Liver

Citric acid:

Species : Rat

NOAEL : 4.000 mg/kg LOAEL : 8.000 mg/kg Application Route : Ingestion Exposure time : 10 Days

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Levamisole hydrochloride:

Ingestion : Symptoms: Nausea, Vomiting, Headache, Dizziness, hypo-

tension

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Levamisole hydrochloride:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): 37,3 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 64 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

oxfendazole:

Toxicity to fish : LC50 (Lepomis macrochirus (Bluegill sunfish)): > 2,7 mg/l

Exposure time: 96 h

LC50 (Oncorhynchus mykiss (rainbow trout)): > 2,5 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 0,059 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202



Levamisole / Oxfendazole Formulation

Version **Revision Date:** SDS Number: Date of last issue: 04.04.2023 30.09.2023 10808164-00003 Date of first issue: 05.07.2022 1.2

Toxicity to algae/aguatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 4

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): > 4

mg/l

10

Exposure time: 72 h

Method: OECD Test Guideline 201

M-Factor (Acute aquatic tox-

Toxicity to daphnia and other :

ic toxicity)

aquatic invertebrates (Chron-

Exposure time: 21 d

Method: OECD Test Guideline 211

NOEC (Daphnia magna (Water flea)): 0,023 mg/l

M-Factor (Chronic aquatic

toxicity)

1

Polyethylene glycol stearate:

Toxicity to fish LC50 (Leuciscus idus (Golden orfe)): > 10.000 mg/l

> Exposure time: 96 h Method: DIN 38412

Toxicity to microorganisms EC10 (Bacteria): > 10.000 mg/l

Exposure time: 16 h

Citric acid:

Toxicity to fish LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 1.535 mg/l

Exposure time: 24 h

Persistence and degradability

Components:

oxfendazole:

Stability in water Hydrolysis: < 5 %(4 d)

Polyethylene glycol stearate:

Biodegradability Result: Readily biodegradable.

Biodegradation: > 70 % Exposure time: 10 d

Method: OECD Test Guideline 302B

Citric acid:

Biodegradability Result: Readily biodegradable.

> Biodegradation: 97 % Exposure time: 28 d

Method: OECD Test Guideline 301B



Levamisole / Oxfendazole Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 1.2 30.09.2023 10808164-00003 Date of first issue: 05.07.2022

Bioaccumulative potential

Components:

oxfendazole:

Partition coefficient: n-

octanol/water

Citric acid:

Partition coefficient: n-

octanol/water

log Pow: -1,72

log Pow: 1,95

Mobility in soil

Components:

oxfendazole:

Distribution among environ-

mental compartments

No data available

: log Koc: 3,2

Other adverse effects

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(oxfendazole)

Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

IATA-DGR

UN/ID No. : UN 3082

Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.

(oxfendazole)

964

Class : 9 Packing group : III

Labels : Miscellaneous

Packing instruction (cargo

aircraft)

16 / 19



Levamisole / Oxfendazole Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 1.2
 30.09.2023
 10808164-00003
 Date of first issue: 05.07.2022

964

Packing instruction (passen-

ger aircraft)

Environmentally hazardous : yes

IMDG-Code

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(oxfendazole)

Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

ANTT

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(oxfendazole)

Class : 9
Packing group : III
Labels : 9
Hazard Identification Number : 90

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

National List of Carcinogenic Agents for Humans - : Not

: Not applicable

(LINACH)

Brazil. List of chemicals controlled by the Federal

Not applicable

Police

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION



Levamisole / Oxfendazole Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 1.2
 30.09.2023
 10808164-00003
 Date of first issue: 05.07.2022

Revision Date : 30.09.2023 Date format : dd.mm.yyyy

Further information

Sources of key data used to compile the Material Safety Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified: Nch - Chilean Norm: NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.



Levamisole / Oxfendazole Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 1.2
 30.09.2023
 10808164-00003
 Date of first issue: 05.07.2022

BR / Z8